Intervention (N=30) | Control (N=31) | |
Demographics/medication | ||
Age, years, mean (SD) | 50.5 (11.1) | 44.9 (12.1) |
Female, n (%) | 21 (70) | 20 (65) |
Disease duration, years, median (p25, p75) | 6 (2–12) | 4 (2–11) |
Synthetic DMARDs, n (%) | 28 (93) | 25 (81) |
Biologic DMARDs, n (%) | 11 (37) | 9 (29) |
Antihypertensive, n (%) | 4 (13) | 4 (13) |
Statins, n (%) | 3 (10) | 0 (0) |
Cardiovascular assessment | ||
Current smoker, n (%) | 6 (20) | 4 (13) |
VO2max (mL/kg/min), mean (SD) | 28.73 (6.41) | 30.75 (7.95) |
Resting HR (beats/min), mean (SD) | 65.3 (11.5) | 66.4 (9.5) |
Systolic BP (mm Hg), mean (SD) | 124 (12) | 125 (16) |
Diastolic BP (mm Hg), mean (SD) | 77 (8) | 78 (11) |
Cholesterol (mmol/L), mean (SD) | 5.2 (0.8) | 5.1 (1.0) |
Triglyceride (mmol/L), median (p25, p75) | 1.1 (0.8–1.9) | 1.0 (0.7–1.4) |
LDL (mmol/L), mean (SD) | 3.2 (0.8) | 3.3 (0.7) |
Body composition | ||
BMI (kg/m2), mean (SD) | 28.6 (4.2) | 27.6 (4.4) |
Total fat%, mean (SD) | 40.3 (7.1) | 38.7 (7.7) |
Truncus fat%, mean (SD) | 43.7 (8.2) | 41.3 (8.7) |
Lean muscle mass (g), mean (SD) | 48 423 (10163) | 48 436 (12066) |
Waist circumference (cm), mean (SD) | 100.1 (10.5) | 96.0 (13.8) |
Disease activity | ||
HS-CRP (g/L), median (p25, p75) | 1.56 (0.9–4.5) | 1.87 (0.86–4.74) |
DAS44, mean (SD) | 2.00 (0.79) | 1.94 (0.76) |
Swollen joints, median (p25, p75) | 0 (0–1) | 0 (0–2) |
Tender joints 66, median (p25, p75) | 5 (1–10) | 6 (1–10) |
PGA (VAS 0–100), mean (SD) | 38.4 (23.7) | 41.6 (20.8) |
MHAQ, median (p25, p75) | 0.32 (0–0.75) | 0.25 (0.13–0.63) |
BMI, Body Mass Index; BP, blood pressure; DAS44, disease activity score of 44 joints; DMARD, disease-modifying antirheumatic drug; HR, heart rate; HS-CRP, high-sensitivity C reactive protein; LDL, low-density lipoprotein; MHAQ, Modified Health Assessment Questionnaire; PGA, patient global assessment; VAS, Visual Analogue Scale; VO2max, maximal oxygen uptake.